Skip to main content

Jim Lindelien, Roland Luethy, Steve McPhail, Donald Holzworth

Premium

TimeLogic founder Jim Lindelien is leaving the company “to pursue new opportunities,” according to a company statement. Lindelien, who started the company in 1994 and engineered its DeCypher accelerated bioinformatics technology, most recently held the position of CTO at TimeLogic. The company's primary technology development duties will now be the responsibility of Roland Luethy, senior bioinformatics research scientist, who joined the company in November. Prior to joining TimeLogic, Luethy served as a research scientist at Amgen from 1993.

Microarray analysis firm Expression Analysis (EA) has tapped Steve McPhail as its new CEO. McPhail joins EA from medical device manufacturer ArgoMed, where he served as executive vice president and COO. Prior to joining ArgoMed, McPhail held senior-level sales, marketing and business development positions for Xanthon, TriPath Imaging, Dynex Technologies, and Abbott Laboratories. He replaces Donald Holzworth, president and CEO of Analytical Sciences, who has acted as EA’s interim CEO since Sept. 2001 when ASI began incubating the company.

 

Filed under

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.